FDA Tightens Accelerated Approval Pathway, Rejects Regenxbio and Disc Medicine
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 03 2026
0mins
The Food and Drug Administration review process for accelerated approvals was meant to drugs for rare diseases to pass the approval process, clearing the drugs based on early biological signs instead of waiting years for definitive proof of real-world outcomes, David Wainer of The Wall Street Journal. Now, however, the accelerated approval pathway isn't closed but has become much narrower and harder to predict. Recently, the FDA issued a string of rejections, including Regenxbio's (RGNX) gene therapy for Hunter Syndrome and Disc Medicine's (IRON) treatment for a blood disorder. In some cases, the agency reversed its own guidelines provided to the companies. In 2025, the FDA greenlighted only nine accelerated approvals, down from 20 in 2024. Other companies in the space include: uniQure (QURE), Moderna (MRNA), Replimune (REPL), and Capricor (CAPR).
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RGNX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RGNX
Wall Street analysts forecast RGNX stock price to rise
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.750
Low
19.00
Averages
29.71
High
45.00
Current: 6.750
Low
19.00
Averages
29.71
High
45.00
About RGNX
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address an array of diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). It is developing RGX-121 for the treatment of Mucopolysaccharidosis type II (MPS II), and RGX-111 to treat Mucopolysaccharidosis Type I.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Multiple Companies Experience Significant Stock Price Gains
- CODX Stock Surge: Co-Diagnostics Inc. (CODX) saw a 55% increase in stock price, closing at $3.71, following the completion of its assay development strategy for the Bundibugyo virus, enhancing its market position in the Congo and Uganda.
- AKTX Breakthrough Clinical Data: Akari Therapeutics Plc (AKTX) rose nearly 50% to $5.14 after demonstrating synergistic activity of AKTX-101 with Adagrasib in KRAS-mutated pancreatic cancer models, with a Phase 1 clinical trial expected to start by mid-2027.
- P3 Health Financial Recovery: P3 Health Partners Inc. (PIII) gained over 40%, closing at $13.86, reporting a net income of $3 million for Q1, a significant turnaround from a $44.2 million loss last year, with full-year revenue projected between $1.5 billion and $1.65 billion.
- Sunshine Drug Approval: Sunshine Biopharma Inc. (SBFM) jumped over 40% to $0.51 after receiving approval for its generic Amoxicillin in Canada, expected to ship by August 2026, further expanding its market share.
See More
REGENXBIO to Participate in Investor Conferences
- Investor Conference Schedule: REGENXBIO will participate in the RBC Capital Markets Global Healthcare Conference on May 20, 2026, in New York, showcasing its latest advancements in gene therapy, which is expected to attract investor interest and enhance the company's visibility.
- Virtual Forum Participation: The company will also take part in the Stifel 2026 Virtual Ophthalmology Forum on May 26, further expanding its influence in the treatment of ocular diseases, particularly in collaboration with AbbVie for wet age-related macular degeneration.
- Gene Therapy Potential: Since its founding in 2009, REGENXBIO has focused on AAV gene therapy and is advancing a late-stage pipeline for rare and retinal diseases, demonstrating its innovative capabilities and competitive edge in the biotechnology sector.
- Patient Treatment Outcomes: The company has treated thousands of patients through its AAV platform, including those receiving Novartis' ZOLGENSMA®, indicating the potential of its therapies to improve patient quality of life, which may attract further investor interest.
See More
REGENXBIO Q1 2026 Earnings Call Highlights
- Clinical Trial Success: REGENXBIO announced that RGX-202's pivotal trial met its primary endpoint, with 93% of 28 patients exceeding the statistical threshold, indicating the gene therapy's potential in treating Duchenne muscular dystrophy and possibly facilitating FDA accelerated approval.
- Patient Dosing Progress: The company has dosed over 50 patients to date, with plans to reach 60 by mid-year, demonstrating significant advancement in clinical trial progression and enhancing market confidence in the therapy's viability.
- Safety Assessment: Among the 31 patients treated, 2 treatment-related serious adverse events (SAEs) were reported, both of which were effectively managed and resolved within weeks, showcasing RGX-202's favorable safety profile that may aid in future commercialization efforts.
- Future Outlook: Management plans to seek approval for RGX-202 in 2027 and anticipates initiating the Phase IIb trial for diabetic retinopathy in Q2, which could yield a $100 million milestone payment, further driving financial growth.
See More
RGX-202 Clinical Trial Achieves Significant Success
- Primary Endpoint Achieved: RGX-202 met its primary endpoint with 93% of patients exceeding the microdystrophin expression threshold, demonstrating high statistical significance and indicating its potential as a treatment for Duchenne muscular dystrophy.
- Strong Safety Profile: The therapy has been administered to over 50 patients with only two treatment-related serious adverse events, both resolved without sequelae, which enhances market confidence in its safety and tolerability.
- Significant Functional Improvement: Interim 12-month functional data showed RGX-202 outperforming external controls across all measures, with a strong correlation between microdystrophin expression and functional improvement, potentially setting a new standard in gene therapy.
- Potential for FDA Accelerated Approval: Supported by robust data and ongoing discussions with the FDA, RGX-202 is on track for potential accelerated approval in 2027, although further data is needed to confirm long-term efficacy, leaving the regulatory path somewhat uncertain.
See More
REGENXBIO Q1 Results Fall Short of Expectations Amid FDA Concerns
- Financial Performance Decline: REGENXBIO's Q1 2026 report revealed a dramatic revenue drop from $89 million to $6.4 million year-over-year, significantly missing analyst expectations of $25.25 million, primarily due to the absence of a $70 million licensing payment and reduced royalties from Novartis' ZOLGENSMA following patent expiration, highlighting the company's revenue vulnerability.
- Widening Net Loss: The company reported a net loss of $90.1 million, or $1.72 per share, compared to a net income of $6.1 million, or $0.12 per share, in the prior year, with losses exceeding Wall Street's average estimate of $1.30 per share, indicating a significant deterioration in financial health.
- FDA Trial Recommendation: Despite RGX-202 achieving a 93% success rate in producing the necessary muscle protein for Duchenne muscular dystrophy, the FDA's recommendation for a randomized controlled trial introduces uncertainty to the accelerated approval timeline, although the company remains optimistic about future discussions with the FDA.
- Market Reaction Positive: Following a 37% drop in stock price due to disappointing earnings, retail sentiment on Stocktwits shifted from 'bullish' to 'extremely bullish', with users predicting the company's market cap could rise from $330 million to $1 billion, reflecting confidence in the company's future potential.
See More
Regenxbiopress Reports Q1 2026 Financial Results with Significant Losses
- Disappointing Earnings: Regenxbiopress reported a Q1 2026 GAAP EPS of -$1.72, missing expectations by $0.42, indicating significant challenges in profitability for the company.
- Dramatic Revenue Decline: The company’s revenue for the first quarter was $6.39 million, a staggering 92.8% year-over-year drop, falling short of the anticipated $18.86 million, reflecting a sharp decline in product sales and market demand.
- Cash Flow Status: As of March 31, 2026, Regenxbiopress expects a balance of $150.5 million in cash, cash equivalents, and marketable securities, which is projected to fund operations into early 2027, highlighting urgency in financial management.
- Future Milestones: Despite the current financial struggles, Regenxbiopress is targeting pivotal data releases for Duchenne, wet AMD, and diabetic retinopathy in 2026, actively seeking clinical advancements to restore market confidence.
See More
Multiple Companies Experience Significant Stock Price Gains
- CODX Stock Surge: Co-Diagnostics Inc. (CODX) saw a 55% increase in stock price, closing at $3.71, following the completion of its assay development strategy for the Bundibugyo virus, enhancing its market position in the Congo and Uganda.
- AKTX Breakthrough Clinical Data: Akari Therapeutics Plc (AKTX) rose nearly 50% to $5.14 after demonstrating synergistic activity of AKTX-101 with Adagrasib in KRAS-mutated pancreatic cancer models, with a Phase 1 clinical trial expected to start by mid-2027.
- P3 Health Financial Recovery: P3 Health Partners Inc. (PIII) gained over 40%, closing at $13.86, reporting a net income of $3 million for Q1, a significant turnaround from a $44.2 million loss last year, with full-year revenue projected between $1.5 billion and $1.65 billion.
- Sunshine Drug Approval: Sunshine Biopharma Inc. (SBFM) jumped over 40% to $0.51 after receiving approval for its generic Amoxicillin in Canada, expected to ship by August 2026, further expanding its market share.
See More
REGENXBIO to Participate in Investor Conferences
- Investor Conference Schedule: REGENXBIO will participate in the RBC Capital Markets Global Healthcare Conference on May 20, 2026, in New York, showcasing its latest advancements in gene therapy, which is expected to attract investor interest and enhance the company's visibility.
- Virtual Forum Participation: The company will also take part in the Stifel 2026 Virtual Ophthalmology Forum on May 26, further expanding its influence in the treatment of ocular diseases, particularly in collaboration with AbbVie for wet age-related macular degeneration.
- Gene Therapy Potential: Since its founding in 2009, REGENXBIO has focused on AAV gene therapy and is advancing a late-stage pipeline for rare and retinal diseases, demonstrating its innovative capabilities and competitive edge in the biotechnology sector.
- Patient Treatment Outcomes: The company has treated thousands of patients through its AAV platform, including those receiving Novartis' ZOLGENSMA®, indicating the potential of its therapies to improve patient quality of life, which may attract further investor interest.
See More
REGENXBIO Q1 2026 Earnings Call Highlights
- Clinical Trial Success: REGENXBIO announced that RGX-202's pivotal trial met its primary endpoint, with 93% of 28 patients exceeding the statistical threshold, indicating the gene therapy's potential in treating Duchenne muscular dystrophy and possibly facilitating FDA accelerated approval.
- Patient Dosing Progress: The company has dosed over 50 patients to date, with plans to reach 60 by mid-year, demonstrating significant advancement in clinical trial progression and enhancing market confidence in the therapy's viability.
- Safety Assessment: Among the 31 patients treated, 2 treatment-related serious adverse events (SAEs) were reported, both of which were effectively managed and resolved within weeks, showcasing RGX-202's favorable safety profile that may aid in future commercialization efforts.
- Future Outlook: Management plans to seek approval for RGX-202 in 2027 and anticipates initiating the Phase IIb trial for diabetic retinopathy in Q2, which could yield a $100 million milestone payment, further driving financial growth.
See More
RGX-202 Clinical Trial Achieves Significant Success
- Primary Endpoint Achieved: RGX-202 met its primary endpoint with 93% of patients exceeding the microdystrophin expression threshold, demonstrating high statistical significance and indicating its potential as a treatment for Duchenne muscular dystrophy.
- Strong Safety Profile: The therapy has been administered to over 50 patients with only two treatment-related serious adverse events, both resolved without sequelae, which enhances market confidence in its safety and tolerability.
- Significant Functional Improvement: Interim 12-month functional data showed RGX-202 outperforming external controls across all measures, with a strong correlation between microdystrophin expression and functional improvement, potentially setting a new standard in gene therapy.
- Potential for FDA Accelerated Approval: Supported by robust data and ongoing discussions with the FDA, RGX-202 is on track for potential accelerated approval in 2027, although further data is needed to confirm long-term efficacy, leaving the regulatory path somewhat uncertain.
See More
REGENXBIO Q1 Results Fall Short of Expectations Amid FDA Concerns
- Financial Performance Decline: REGENXBIO's Q1 2026 report revealed a dramatic revenue drop from $89 million to $6.4 million year-over-year, significantly missing analyst expectations of $25.25 million, primarily due to the absence of a $70 million licensing payment and reduced royalties from Novartis' ZOLGENSMA following patent expiration, highlighting the company's revenue vulnerability.
- Widening Net Loss: The company reported a net loss of $90.1 million, or $1.72 per share, compared to a net income of $6.1 million, or $0.12 per share, in the prior year, with losses exceeding Wall Street's average estimate of $1.30 per share, indicating a significant deterioration in financial health.
- FDA Trial Recommendation: Despite RGX-202 achieving a 93% success rate in producing the necessary muscle protein for Duchenne muscular dystrophy, the FDA's recommendation for a randomized controlled trial introduces uncertainty to the accelerated approval timeline, although the company remains optimistic about future discussions with the FDA.
- Market Reaction Positive: Following a 37% drop in stock price due to disappointing earnings, retail sentiment on Stocktwits shifted from 'bullish' to 'extremely bullish', with users predicting the company's market cap could rise from $330 million to $1 billion, reflecting confidence in the company's future potential.
See More
Regenxbiopress Reports Q1 2026 Financial Results with Significant Losses
- Disappointing Earnings: Regenxbiopress reported a Q1 2026 GAAP EPS of -$1.72, missing expectations by $0.42, indicating significant challenges in profitability for the company.
- Dramatic Revenue Decline: The company’s revenue for the first quarter was $6.39 million, a staggering 92.8% year-over-year drop, falling short of the anticipated $18.86 million, reflecting a sharp decline in product sales and market demand.
- Cash Flow Status: As of March 31, 2026, Regenxbiopress expects a balance of $150.5 million in cash, cash equivalents, and marketable securities, which is projected to fund operations into early 2027, highlighting urgency in financial management.
- Future Milestones: Despite the current financial struggles, Regenxbiopress is targeting pivotal data releases for Duchenne, wet AMD, and diabetic retinopathy in 2026, actively seeking clinical advancements to restore market confidence.
See More
